Search

Home > New FDA Approvals > 019 - Genentech’s sBLA for Avastin (bevacizumab) as Front-Line Treatment for Advanced Ovarian Cancer; VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for MDD; Renishaw Wins FDA Approval for Neurosurgery Planning Software
Podcast: New FDA Approvals
Episode:

019 - Genentech’s sBLA for Avastin (bevacizumab) as Front-Line Treatment for Advanced Ovarian Cancer; VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for MDD; Renishaw Wins FDA Approval for Neurosurgery Planning Software
Category: Science & Medicine
Duration: 0
Publish Date: 2017-10-27 06:00:00
Description:

October 27, 2017

0:27 FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer

https://www.gene.com/media/press-releases/14685/2017-10-25/fda-accepts-genentechs-supplemental-biol

3:24 VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder

https://www.vistagen.com/news-media/press-releases/detail/71/vistagen-announces-fda-authorization-to-initiate-phase-2

5:03 Renishaw Wins FDA Approval for Neurosurgery Planning Software

http://www.fdanews.com/articles/184134-renishaw-wins-fda-approval-for-neurosurgery-planning-software
Total Play: 0